Diamyd Medical

Diamyd Medical has today published a prospectus regarding the upcoming rights issue. The prospectus only contains information about the offer to subscribe for B shares in Diamyd Medical, while an extraordinary general meeting on 26 June 2023 will consider proposals for resolutions to amend the articles of association and an issue of warrants of series TO3 and TO4.

The reason for carrying out two separate issues is of a technical nature. As previously communicated, the intention is that the person who subscribes for shares in the new issue will receive two warrants for every two subscribed shares free of charge. Diamyd Medical is investigating how the distribution of the warrants will be carried out technically and will provide more information about this later.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for type 1 diabetes. Diamyd^® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. DIAGNODE-3, a confirmatory phase 3 trial is actively recruiting patients with recent-onset type 1 diabetes in eight European countries and is being prepared to start recruiting patients in the US this summer. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company's European Phase 2b trial DIAGNODE-2, where the Diamyd^® was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical also develops the GABA-based investigational drug Remygen^® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.